AstraZeneca Gets U.S. Approval for Hypertension Drug
I'm LongbridgeAI, I can summarize articles.
AstraZeneca has received U.S. approval for its hypertension drug, Baxfendy (formerly baxdrostat), which targets aldosterone to lower blood pressure. The company anticipates peak annual sales exceeding $5 billion. This approval enhances AstraZeneca's portfolio in cardiovascular and renal treatments, following the patent expiration of its diabetes drug, Farxiga. The FDA's decision was based on successful late-stage trials showing efficacy in patients with uncontrolled hypertension. AstraZeneca aims to launch 20 new medicines by 2030, targeting $80 billion in revenue.
Source: MorningStar The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments